Fig. S15: Comparative assessments of the anti-tumor efficacy of CAR T cells in the SKOV3-CD19 model. $5 \times 10^5$ SKOV3-CD19 tumor cells were injected subcutaneously into NSG mice. Seven days later, $5 \times 10^6$ CAR T cells were injected intravenously and bioluminescence imaging was performed weekly over a 30-day period. The p-value = 0.0016 for the comparisons of the tumor burden at day 30 (Mann-Whitney two tailed test) for CD19.4-1BBz vs CD19.28z-CD137L.